Back to top
more

BioLineRx (BLRX)

(Delayed Data from NSDQ)

$0.66 USD

0.66
186,723

+0.02 (2.56%)

Updated Apr 19, 2024 04:00 PM ET

After-Market: $0.65 -0.01 (-0.99%) 5:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Fiscal Year End for BioLineRx Ltd falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 43 51 57 23 27
Receivables 1 1 0 0 1
Notes Receivable 0 0 0 0 0
Inventories 2 0 0 0 0
Other Current Assets 1 0 0 0 0
Total Current Assets 47 52 57 23 28
Net Property & Equipment 0 1 1 1 2
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 15 22 22 22 22
Deposits & Other Assets 0 0 0 0 0
Total Assets 64 76 81 47 54
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 14 9 7 7 9
Current Portion Long-Term Debt 3 2 3 3 3
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 0 0 0 0
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 13 0 0 0 0
Total Current Liabilities 31 11 10 11 12
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 7 9 0 3 6
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 12 5 2 10 1
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 51 26 13 25 20
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 31 27 21 10 5
Capital Surplus 372 354 353 292 278
Retained Earnings -391 -330 -305 -278 -248
Other Equity 0 0 0 -1 -1
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 13 51 68 22 33
Total Liabilities & Shareholder's Equity 64 76 81 47 54
Total Common Equity 13 51 68 22 33
Shares Outstanding 72.40 61.50 47.60 32.20 7.40
Book Value Per Share 0.18 0.83 1.43 0.68 4.51

Fiscal Year End for BioLineRx Ltd falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 43 26 33 43
Receivables NA 1 0 0 0
Notes Receivable NA 0 0 0 0
Inventories NA 2 1 0 0
Other Current Assets NA 1 1 2 1
Total Current Assets NA 47 29 35 44
Net Property & Equipment NA 0 1 1 1
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 15 22 22 22
Deposits & Other Assets NA 0 0 0 0
Total Assets NA 64 53 59 69
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 14 11 9 9
Current Portion Long-Term Debt NA 3 3 3 3
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 13 0 0 0
Total Current Liabilities NA 31 15 12 12
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 7 8 9 8
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 15 15 8
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 51 40 38 30
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 31 28 27 27
Capital Surplus NA 372 362 355 354
Retained Earnings NA -391 -377 -361 -342
Other Equity NA 0 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 13 13 21 39
Total Liabilities & Shareholder's Equity NA 64 53 59 69
Total Common Equity 0 13 13 21 39
Shares Outstanding 72.40 72.40 61.50 61.50 61.50
Book Value Per Share 0.00 0.18 0.21 0.34 0.64